Related Experiment Video
Updated: Jun 10, 2026

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
Covalent crosslinking of tumor antigens stimulates an antitumor immune response
Yanping Wang1, Xiang-Yang Wang, John R Subjeck
1Department of Surgery, Division of Urology, Cedars-Sinai Medical Center, 8635 West 3rd Street, Suite 1070W, Los Angeles, CA 90048, USA.
Abstract:
In murine renal cell carcinoma and melanoma models, vaccination with crosslinked tumor antigen in the absence of other adjuvants inhibited the growth of RENCA and B16 tumors. Vaccination with crosslinked antigens (CA9 or gp100) enhanced the cellular immune response as measured by ELISPOT and cytotoxicity assays. Crosslinking antigens enhanced delivery of antigen to bone marrow derived dendritic cells, which were capable of internalizing and processing the antigens. Dendritic cells pulsed with crosslinked antigen were effective in stimulating antigen-specific CD8+ T lymphocyte proliferation and interferon-γ secretion. Crosslinking tumor antigens is a simple and effective strategy for enhancing tumor vaccines.
Related Concept Videos
Tumor Immunotherapy
The Tumor Microenvironment
The Tumor Microenvironment
Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
